Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 141Lung Neoplasms 51Pancreatic Neoplasms 30Non-Squamous Non-Small Cell Lung Cancer 18Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Glioblastoma 13Gliosarcoma 12Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Adenocarcinoma, Bronchiolo-Alveolar 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Squamous Cell 7Carcinoma, Renal Cell 7Astrocytoma 6Oligodendroglioma 5Carcinoma 5Urinary Bladder Neoplasms 4Liver Neoplasms 4Glioma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Low-Level Light Therapy 2tremelimumab 1ruxolitinib 1durvalumab 1bavituximab 1Vitamin E 1Tenofovir 1Specimen Handling 1Sorafenib 1Simvastatin 1Pentoxifylline 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Hypothermia, Induced 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fibrosis × Erlotinib Hydrochloride × Clear all
NCT02273362 2024-03-26

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

National Cancer Institute (NCI)

Phase 1/2 Completed
25 enrolled 10 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡